UCB, a global biopharmaceutical company, is presenting its research on generalized myasthenia gravis (gMG) at two annual meetings. It will present additional results from the MycarinG and RAISE studies on its drugs rozanolixizumab-noli and zilucoplan. Both drugs, recently approved by the US FDA and Japanese authorities, are under review by the European Medicines Agency for the treatment of adults with gMG. UCB is also assessing the drugs in pediatric patients with gMG.
Wall Street’s Leaders and Laggards of 2024
2024 was a mixed year for biopharma stocks, with the iShares Biotechnology ETF and SPDR S&P Biotech ETF experiencing small decreases. Federal Reserve decisions caused
